Pharma and Healthcare Insight

Pharma & Healthcare Insight brings you analysis of regional trends, regulatory changes, projects and investments plus competitive intelligence on the growth strategies of leading companies in the sector

See Prices or Subscribe

Key stories from this month's issue...

Industry Trend Analysis - Regional Diabetes Treatment Demand To Be Driven By Two Markets - JULY 2017

Americas June 2017 / Latin America / Industry

The Latin America region represents a significant opportunity for diabetes-related medicines given poor diet, low levels of physical activity and a high prevalence of obesity. Levels of diagnosis and access to medicines are poor; therefore, drugmakers will need to cooperate in access schemes and disease prevention programmes to exploit the region's underlying demand. We highlight Mexico as the key market in the region.


Industry Trend Analysis - Slim Chance In Asia Pacific Agreement Negotiations To Soften IP Requirements - JULY 2017

Asia June 2017 / Asia / Industry

Wholesale renegotiation of the intellectual property provisions of the Trans Pacific Partnership would be laborious and consequently are unlikely. However, there is a possibility that the terms may be changed, as many of the existing provisions came from US negotiators. Other countries involved in the agreement have economic reasons to take a softer stance that would allow more generics. This is also true of the Regional Comprehensive Economic Partnership negotiations. However, Japan's apparent stand on these negotiations suggests that hardened attitudes will prevail in both agreement negotiations.


Industry Trend Analysis - Divergent Opportunities For Cardiovascular Disease Medicines - JULY 2017

Emerging Europe June 2017 / Europe / Industry

Opportunities for drugmakers specialised in the therapeutic field of cardiovascular diseases are significant across the Europe region. However, we note that there is a division between the opportunities in the Western Europe and Central and Eastern Europe regions. In the more developed West, for innovative medicine manufacturers we note that cost-containment poses a risk. In the East, there is considerable demand for preventative generic medicines.


Industry Trend Analysis - Targeted Prevention Strategies Will Boost Market Access For Cardiovascular Drugmakers - JULY 2017

Middle East & Africa June 2017 / Middle East / Industry

The demand for cardiovascular disease treatments in the Middle East and North Africa region will be robust over the long term. To leverage the associated commercial opportunities, multinational pharmaceutical firms will have to adopt country-specific strategies, given the differences in healthcare access, affordability levels and competition. The Gulf States will retain their position as the most attractive sub-region for innovative drugmakers in this therapeutic area, yet companies will have to adapt with the heightened risk of pricing pressures as respective governments seek to contain healthcare costs.


Industry Trend Analysis - Sanofi/WRAIR Deal Heightens Argument Around US Investment - JULY 2017

Western Europe June 2017 / France / Industry

The ongoing debate around the Zika vaccine deal between the US Army and Sanofi is set to continue throughout the R&D process. There is little interest for pharmaceutical companies to spend a large amount of money on developing a novel vaccine and there is risk to these not being profitable. If there are changes in the future licensing deals, due to ongoing controversy, this will diminish pharmaceutical companies investing in future vaccine deals, which can increase the risk of disease outbreaks.